ArticleCell death & disease2026
Neurochondrin drives colorectal cancer progression by modulating the PODXL-Ezrin axis and mitochondrial function.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Neurochondrin (NCDN) has been recently identified as overexpressed in liver metastatic colorectal cancer (CRC) cells compared to poorly metastatic isogenic counterparts. While its cellular function and role in cancer and CRC remain unknown, patient survival data indicate that elevated NCDN levels are associated with poor prognosis. After validating these observations in an independent patient cohort, we sought to investigate the role of NCDN in CRC progression using isogenic CRC cell models comprising poorly metastatic KM12C and liver-metastatic KM12SM cells, and poorly metastatic SW480 and lymph node-metastatic SW620 cells. Stable silencing of NCDN expression in these cell lines resulted in a significant reduction in their tumorigenic and metastatic properties in vitro. Furthermore, in vivo assays using nude mice and the KM12 cell model demonstrated that NCDN is essential for tumor initiation, growth, and liver metastasis of CRC cells. Proteomic profiling of NCDN-silenced cells uncovered a set of dysregulated proteins associated with cell adhesion, invasion, cell death, and differentiation, and mitochondrial dysfunction, emerging NCDN-PODXL-EZR axis as a critical mediator of CRC progression and involved in liver metastasis. Our findings position NCDN and their associated dysregulated proteins as drivers of CRC progression and promising targets for further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.